1000.0000 3.75 (0.38%)
NSE Apr 10, 2026 15:31 PM
Volume: 210.8K
 

1000.00
0.38%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma has gained 15.43% in the last 1 Month
More from Strides Pharma Science Ltd.
Recommended